Key result
Novel imidazole-based compounds show preferential AT1 receptor binding with high affinity comparable to losartan.
Why the study?
Developing small molecules with defined AT1 versus AT2 binding profiles remains important for both therapeutic and mechanistic studies.
Novel imidazole-based compounds demonstrated high and selective binding affinity for the AT1 receptor, comparable to losartan, providing a basis for further therapeutic development.
Should not change ARB prescribing; leaves open further preclinical development of these AT1 ligands.
The angiotensin II type 1 (AT1) receptor is a key component of the renin–angiotensin system (RAS) and a validated target for cardiovascular and renal disorders. Developing small molecules with defined AT1 versus AT2 binding profiles remains important for both therapeutic and mechanistic studies. Here, a series of novel imidazole-based compounds was synthesized and evaluated for their binding affinities toward angiotensin II type 1 (AT1) and type 2 (AT2) receptors. Binding studies were conducted by measuring the displacement of radiolabeled [3H]-angiotensin II ([3H]-AII) in PLC-PRF-5 human hepatoma cells for AT1 receptors and calf cerebellum membranes for AT2 receptors. Structure–activity relationship (SAR) analysis revealed that sulfonamide substitution significantly enhanced AT1 receptor affinity, whereas sterically hindered derivatives and ester-containing compounds were less active. Molecular docking studies using the AT1 receptor crystal structure (PDB: 8TH4) rationalized the observed activity trends. The most active compound showed high AT1 affinity (Ki = 5 nM), comparable to losartan, and all compounds displayed preferential binding for AT1 over AT2 receptors.
No takes yet. Share an insight, caveat, or question.
Descamps et al. (2026) studied this question. Imidazole-based compounds vs. losartan was evaluated on AT1 and AT2 receptor binding affinities. Novel imidazole-based compounds demonstrated preferential binding for AT1 over AT2 receptors, with the most active compound showing high AT1 affinity (Ki = 5 nM) comparable to losartan.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: